‘Many patients on medication for chronic diseases have to be monitored regularly,’ she said. General practice activity in Australia 2007-08 describes general practice activity predicated on an example of 95,300 patient encounters with 953 randomly selected GPs. General practice activity in Australia 1998-99 to 2007-08: 10 year data tables, highlights changes over the last a decade in GP workload and demand.. A decade of change generally practice It is not only the sufferers in GP surgeries who are getting older, according to two new reports released today by the Australian Institute of Health insurance and Welfare and the Australian General Practice Statistics and Classification Center, an AIHW collaborating device located at the University of Sydney. ‘Some of the very most noticeable changes generally practice over the last decade include the reducing proportion of youthful GPs, an evergrowing proportion of female GPs, a decline in the number of small methods, a decline in prescriptions and a steady increase in pathology screening,’ Professor Helena Britt said.GAAP SG&A expenses had been $56.1 million for Q2 2010, compared to $42.7 million for Q2 2009. As of 30 June, 2010, the Company experienced $248.8 million in cash, cash equivalents and marketable securities, in comparison to $204.7 million at March 31, 2010. ‘Our achievements in the second quarter, including landmark accomplishments in Japan and amazing progress inside our lead pipeline programs, reflect clinical benefits provided by the innovative complement-blockade technology of Soliris, and the continued strengthening of our growing global operations,’ said Leonard Bell, M.D., CEO of Alexion. ‘We anticipate the chance to serve more sufferers with PNH in the coming quarters, while progressing our aHUS and transplant applications to serve individuals with other severe and ultra-rare disorders in the years forward.’ Second Quarter 2010 Research and Development Progress: Through the second quarter, Alexion made continued improvement on advancing the advancement of Soliris as a treatment for patients experiencing additional rare and severe complement-mediated disorders.